Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience
To the best of our knowledge, this is the first real-world study to demonstrate that adding ruxolitinib to a standard methylprednisolone regimen provides an effective and safe first-line treatment for aGVHD.
Authors
- Zhijie Kang
- Yuan Huo
- Dong Chi Zhou (ORCID: https://orcid.org/0000-0001-7101-4125)
- Jinsong Yan (ORCID: https://orcid.org/0000-0003-4109-2602)
- Yang Yan (ORCID: https://orcid.org/0000-0002-1743-0184)
- Ying Wang (ORCID: https://orcid.org/0000-0003-2121-7025)
- Liyuan Ma
- Yonglan Huang (ORCID: https://orcid.org/0000-0002-7527-3754)
- Guangjun Fan
Institutions
- Dalian Medical University (CN)
- Yingkou Institute of Technology (CN)
- Shanghai Ninth People's Hospital (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1621708
- Citations
- 2
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Dalian Medical University